Exhaled breath condensate biomarkers for lung cancer

Campanella, Alessandro; Summa, Simona De; Tommasi, Stefania

doi:10.1088/1752-7163/ab2f9f

Cited by 53 publications

(35 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGLN2 methylation was associated with hypoxic features while the association of HIF-1α and EGLN2 enabled the identification of patients with poorer OS [ 197 ]. Other targets linked to hypoxia such as Cdkn2a (cyclin-dependent kinase inhibitor 2A) or Vdac1 (voltage-dependent anion-selective channel 1) [ 198 , 199 ] were identified in an innovative approach aiming to explore novel biomarkers for lung cancer in exhaled breath [ 200 , 201 ].…”

Section: Available Tools To Detect Hypoxia In Clinical Practicementioning

confidence: 99%

Hypoxia in Lung Cancer Management: A Translational Approach

Ancel

Perotin

Dewolf

et al. 2021

Cancers

View full text Add to dashboard Cite

Lung cancer represents the first cause of death by cancer worldwide and remains a challenging public health issue. Hypoxia, as a relevant biomarker, has raised high expectations for clinical practice. Here, we review clinical and pathological features related to hypoxic lung tumours. Secondly, we expound on the main current techniques to evaluate hypoxic status in NSCLC focusing on positive emission tomography. We present existing alternative experimental approaches such as the examination of circulating markers and highlight the interest in non-invasive markers. Finally, we evaluate the relevance of investigating hypoxia in lung cancer management as a companion biomarker at various lung cancer stages. Hypoxia could support the identification of patients with higher risks of NSCLC. Moreover, the presence of hypoxia in treated tumours could help clinicians predict a worse prognosis for patients with resected NSCLC and may help identify patients who would benefit potentially from adjuvant therapies. Globally, the large quantity of translational data incites experimental and clinical studies to implement the characterisation of hypoxia in clinical NSCLC management.

show abstract

Section: Available Tools To Detect Hypoxia In Clinical Practicementioning

confidence: 99%

Hypoxia in Lung Cancer Management: A Translational Approach

Ancel

Perotin

Dewolf

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Other kinds of omic data have also been involved in HMDB, which made it more compatible with the increasing number of multi-omic or systems biology studies [ 16 ]. Recently, efforts have been made on searching lung cancer markers in exhaled breath condensate (EBC) where genes [ 45 ] and proteins [ 46 ] could be detected. With different sampling technique, multi-omics data including VOCs, genes and proteins could be acquired in exhaled breath, simultaneously.…”

Section: Discussionmentioning

confidence: 99%

Exhaled metabolic markers and relevant dysregulated pathways of lung cancer: a pilot study

Zou

Jiang³

et al. 2022

Annals of Medicine

View full text Add to dashboard Cite

Introduction The clinical application of lung cancer detection based on breath test is still challenging due to lack of predictive molecular markers in exhaled breath. This study explored potential lung cancer biomarkers and their related pathways using a typical process for metabolomics investigation. Material and methods Breath samples from 60 lung cancer patients and 176 healthy people were analyzed by GC-MS. The original data were GC-MS peak intensity removing background signal. Differential metabolites were selected after univariate statistical analysis and multivariate statistical analysis based on OPLS-DA and Spearman rank correlation analysis. A multivariate PLS-DA model was established based on differential metabolites for pattern recognition. Subsequently, pathway enrichment analysis was performed on differential metabolites. Results The discriminant capability was assessed by ROC curve of whom the average AUC and average accuracy in 100-fold cross validations were 0.871 and 0.787, respectively. Eight potential biomarkers were involved in a total of 18 metabolic pathways. Among them, 11 metabolic pathways have p -value smaller than .1. Discussion Some pathways among them are related to risk factors or therapies of lung cancer. However, more of them are dysregulated pathways of lung cancer reported in studies based on genome or transcriptome data. Conclusion We believe that it opens the possibility of using metabolomics methods to analyze data of exhaled breath and promotes involvement of knowledge dataset to cover more volatile metabolites. Clinical significance Although a series of related research reported diagnostic models with highly sensitive and specific prediction, the clinical application of lung cancer detection based on breath test is still challenging due to disease heterogeneity and lack of predictive molecular markers in exhaled breath. This study may promote the clinical application of this technique which is suitable for large-scale screening thanks to its low-cost and non-invasiveness. As a result, the mortality of lung cancer may be decreased in future. Key messages In the present study, 11 pathways involving 8 potential biomarkers were discovered to be dysregulated pathways of lung cancer. We found that it is possible to apply metabolomics methods in analysis of data from breath test, which is meaningful to discover convinced volatile markers with definite pathological and histological significance.

show abstract

“…Sensitivity or specificity of early detection may be improved through panels of cancer antigens measured in serum or in plasma, or even novel NGS of circulating tumour DNA, which could improve diagnostic accuracy [32]. Further ahead, options may include the use of exhaled breath condensate for cancer detection, or enhanced cytology techniques based on sophisticated image analysis algorithms and with artificial intelligence, which could add sputum as an additional useful non-invasive body fluid to identify biomarkers in the context of lung cancer screening [33].…”

Section: Non-small Cell Lung Cancermentioning

confidence: 99%

Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology

Horgan¹,

Ciliberto²,

Conté³

et al. 2020

Biomed Hub

View full text Add to dashboard Cite

Rapid and continuing advances in biomarker testing are not being matched by take-up in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. This paper sets out the potential of biomarker testing, the unfolding precision and range of possible diagnosis and prediction, and the many obstacles to adoption. It offers case studies of biomarker testing in breast, ovarian, prostate, lung, thyroid and colon cancers, and derives specific lessons as to the potential and actual use of each of them. It also draws lessons about how to improve access and alignment, and to remedy the data deficiencies that impede development. And it suggests solutions to outstanding issues – notably including funding and the tangled web of obtaining reimbursement or equivalent coverage that Europe’s fragmented health system implies. It urges a European evolution towards an initial minimum testing scenario, which would guarantee universal access to a suite of biomarker tests for the currently most common conditions, and, further into the future, to an optimum testing scenario in which a much wider range of biomarker tests would be introduced and become part of a more sophisticated health system articulated around personalised medicine. For exploiting genomics to the full, it argues the need for a new policy framework for Europe. Biomarker testing is not an issue that can be treated in isolation, since the purpose of testing is to improve health. Its use is therefore always closely linked to specific health challenges and needs to be viewed in the broader policy context in the EU and more widely. The paper is the result of extensive engagement with experts and decision makers to develop the framework, and consequently represents a wide consensus of views on how healthcare systems should respond from push and pull factors at local, national and cross-border and EU level. It contains strong views and clear recommendations springing from the convictions of patients, clinicians, academics, medicines authorities, HTA bodies, payers, the diagnostic, pharmaceutical and ICT industries, and national policy makers.

show abstract

Exhaled breath condensate biomarkers for lung cancer

Cited by 53 publications

References 95 publications

Hypoxia in Lung Cancer Management: A Translational Approach

Hypoxia in Lung Cancer Management: A Translational Approach

Exhaled metabolic markers and relevant dysregulated pathways of lung cancer: a pilot study

Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology

Contact Info

Product

Resources

About